ArticleNeuro-oncology advances
Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3-21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3-4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.